Table 2 Respiratory and clinical characteristics before and after initiation of MI-E therapy.

From: Provision, cough efficacy and treatment satisfaction of mechanical insufflation-exsufflation in a large multicenter cohort of patients with amyotrophic lateral sclerosis

Variable

Number of patients, n

Baseline survey, M (SD)

Follow-up survey, M (SD)

Difference, M (SD, 95% CI)

p valuea

db

ALSFRS-R total score (max. 48)

371

32.1 (7.1)

26.5 (9.0)

5.57 (6.30, 4.92–6.21)

 < 0.001

0.884

ALSFRS-R respiratory sub-scale score (max. 12)

369

10.3 (2.5)

8.9 (3.5)

1.42 (2.80, 1.14–1.71)

 < 0.001

0.510

CPF in l/min

186

184.3 (84.9)

160.1 (100.3)

24.29 (95.59, 10.46–38.12)

 < 0.001

0.254

Cough deficiency

363

6.4 (2.3)

5.7 (2.4)

0.7 (n/a, n/a-n/a)

 < 0.001

n/a

SVC in %

196

68.1 (23.3)

55.8 (26.7)

12.25 (17.61, 9.77–14.73)

 < 0.001

0.539

SpO2

201

95.6 (2.4)

95.0 (2.6)

0.62 (2.92, 0.21–1.02)

 < 0.001

0.211

BMI

337

24.2 (4.5)

23.5 (4.5)

0.69 (1.71, 0.51–0.88)

 < 0.001

0.405

Weight

342

69.9 (15.1)

68.0 (15.3)

1.81 (5.77, 1.20–2.42)

 < 0.001

0.314

  1. aMean difference was accessed by t-test or Wilcoxon signed rank test. A p value < 0.05 was considered as statistically significant.
  2. bEffect size was classified as follows: low effect size: d ≥ 0.2, medium effect size: d ≥ 0.5 and high effect size: d ≥ 0.8 (Cohens, 1988).
  3. CPF, Cough Peak Flow; SVC, slow vital capacity; SpO, peripheral oxygen saturation; d, effect size; Cohen´s d; M, mean; SD, standard deviation; n, number of patients.
  4. The assessments of the measurements were performed at time of indication for MI-E therapy (baseline survey) and after initiation of MI-E therapy (follow-up survey).
Back to article page